Epigenetic editing startup Moonwalk shifts focus to siRNA for obesitynews2026-02-13T16:14:41+00:00February 13th, 2026|Endpoints News|
Lundbeck’s migraine prevention drug succeeds in Phase 2, advancing new therapy classnews2026-02-13T15:55:35+00:00February 13th, 2026|Endpoints News|
Moderna’s flu shot dilemma muddies 2028 break-even guidancenews2026-02-13T15:55:13+00:00February 13th, 2026|Endpoints News|
Updated: Ultragenyx to lay off about 130 employees, resubmit rare disease application againnews2026-02-13T00:50:07+00:00February 13th, 2026|Endpoints News|
Controversy around FDA’s Prasad rises again after Moderna rejection, behavior allegationsnews2026-02-12T16:24:16+00:00February 12th, 2026|Endpoints News|
Even Europeans don’t see a future in Euro biopharma anymorenews2026-02-12T14:27:08+00:00February 12th, 2026|Endpoints News|
Lyell starts first head-to-head CAR-T therapy trialnews2026-02-12T12:35:01+00:00February 12th, 2026|Endpoints News|
BridgeBio’s dwarfism drug succeeds in Phase 3, adding to recent late-stage winsnews2026-02-12T12:30:41+00:00February 12th, 2026|Endpoints News|
Sanofi invests in China startup GluBio in developing molecular glue for sickle cellnews2026-02-11T12:00:02+00:00February 11th, 2026|Endpoints News|
Upstream Bio’s stock slides on Phase 2 severe asthma data for verekitugnews2026-02-11T11:57:14+00:00February 11th, 2026|Endpoints News|
